Clinical Trial

Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy

Study acronym: TaRGET
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-12-08; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Recruiting 2025-04-01
Trial Details
NCT Number NCT06174220
Lead Sponsor Hamilton Health Sciences Corporation
Collaborators: Canadian Institutes of Health Research (CIHR), Canadian SADS, AMO Pharma Limited, Hearts in Rhythm Organization (HiRO), Population Health Research Institute
Conditions Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Enrollment 120 participants
Start Date 2025-03-21
Primary Completion 2027-02-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-12